TUESDAY, March 29, 2022 (HealthDay News) — Despite months of intense lobbying by patient advocates, federal health officials on Monday posted a largely negative review of an experimental drug for the devastating illness known as amyotrophic lateral sclerosis (ALS). In an analysis of Amylyx Pharmaceuticals’ drug, known for now onlyContinue Reading